FDA orders vision risk warnings on all GLP-1 drugs

The US Food and Drug Administration is requiring the makers of all GLP-1 drugs to add warnings about a potential increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.

Why it matters: GLP-1 drugs, including Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Mounjaro and Zepbound, are among the world's best selling medicines, so a class wide label change reaches millions of patients even though the condition is rare and no causal link has been established.

Data as of US Food and Drug Administration safety communication of November 9, 2026, read on fda.gov in this run; the labeling requirement and the NAION description are the FDA's own. The trial rate figures and analyst reaction are CNBC reporting of November 10, 2026, read in full via the estate browser route. Developing item.

The Food and Drug Administration said on Monday that it is requiring application holders for all GLP-1 receptor agonist medications to add information to the Warnings and Precautions section of their labeling about a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION. The condition, caused by decreased blood flow to the front of the optic nerve, can produce acute, painless decreased vision in one eye, including permanent vision loss, and cases have been reported for every marketed GLP-1 product, CNBC reported.

The FDA said a causal relationship has not been established. An analysis of 126 trials with more than 134,000 patients, cited by CNBC from the agency’s review, found 6.4 cases of NAION per 100,000 patient years among GLP-1 users against 3.8 among patients on other treatments or placebos. Citi analysts said the class wide action should have limited effect on GLP-1 uptake, given the condition’s rarity and the drugs’ established benefits.

FDA orders vision risk warnings on all GLP-1 drugs

Sources